



# Changes to CDC Vaccine Recommendations in 2025 and 2026

April 28, 2026

Since U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. (hereinafter, HHS Secretary) was sworn in on [February 13, 2025](#), HHS has changed several long-standing federal vaccine recommendations. In addition, HHS has issued recommendations for vaccines newly licensed (i.e., approved) by the Food and Drug Administration. This CRS Insight summarizes vaccine recommendation changes to date and related developments.

For [over 60 years](#) prior to 2025, the [Advisory Committee on Immunization Practices](#) (ACIP)—a committee of scientific and health experts in immunization—made vaccine recommendations to HHS, particularly the Centers for Disease Control and Prevention (CDC). For each vaccine recommendation, ACIP typically reviewed scientific evidence, developed a new or updated recommendation, and then voted on the recommendation. ACIP’s recommendation was subsequently reviewed by the CDC Director, who decided whether to adopt it as an official HHS/CDC recommendation.

ACIP also voted annually, typically in [the fall](#), to update the following year’s childhood/adolescent and adult [immunization schedules](#). These consolidated schedules list CDC’s recommendations for vaccines routinely offered to patients, presented in a format to aid clinical practice. Many [federal and state laws](#) reference ACIP’s recommendations and CDC’s immunization schedules.

In 2025 and 2026, HHS changed several aspects of policy and practice related to ACIP and CDC vaccine recommendations. On [June 9, 2025](#), the HHS Secretary removed all 17 then-sitting ACIP committee members and subsequently [appointed](#) new members. At the June, September, and December [meetings](#), the reconstituted committee voted on several vaccine recommendations, which CDC/HHS subsequently adopted. HHS also changed multiple vaccine recommendations without consulting ACIP, including for the entire childhood immunization schedule in January 2026. The changes made after June 11, 2025, are currently stayed by a district court [order](#), meaning that they presently have no effect and the agency cannot implement them (as discussed further below).

## HHS Vaccine Recommendation Changes in 2025 and 2026

The following changes in federal vaccine recommendations include both changes in ACIP recommendations that were officially adopted as [CDC/HHS recommendations](#) and CDC/HHS changes

**Congressional Research Service**

<https://crsreports.congress.gov>

IN12684

made without ACIP consultation. The following does not summarize changes to travel vaccine recommendations.

### April 15-16, 2025 (ACIP Meeting)

- ACIP [recommended](#) that the meningitis vaccine, MenACWY, may be used when both MenACWY and MenB vaccines are indicated at the same visit.
- ACIP [recommended](#) that adults 50-59 years of age who are at increased risk of severe RSV disease receive a single dose of RSV vaccine.

### May 27, 2025

The HHS Secretary [posted on X](#) that CDC would stop recommending COVID-19 vaccines for children and pregnant women.

- CDC’s webpages subsequently reflected changes to COVID-19 vaccine recommendations, which changed from all [children](#) to a “shared clinical-decision making” recommendation (SCDM), where patients and providers discuss the benefits and risks of vaccination to determine whether to vaccinate; for [pregnant women](#), the recommendation changed to “no guidance/not applicable.”

### June 25-26, 2025 (ACIP Meeting)

- ACIP recommended one dose of a new RSV immunization, [clesrovimab](#), for infants eight months of age or less born during or entering their first RSV season who are not protected by maternal vaccination. ACIP did not issue a preferential recommendation for either of the approved RSV immunizations for this population (i.e., [clesrovimab](#) and [nirsevimab](#)).
- ACIP reaffirmed its [recommendations](#) for routine annual influenza (flu) vaccination for all persons aged six months and older who do not have contraindications for the 2025-2026 season.
  - ACIP [recommended](#) to discontinue use of flu vaccines that contain thimerosal.

### September 18-19, 2025 (ACIP Meeting)

- ACIP changed [COVID-19 vaccine recommendations](#) for adults and children from universal to SCDM.
- ACIP [recommended](#) against the use of measles, mumps, rubella and varicella (MMRV) vaccines. Children were recommended to receive separate varicella vaccine and MMR vaccines. Prior to this change, the MMRV vaccine was [preferentially recommended](#) over separate vaccinations in certain situations.

### December 4-5, 2025 (ACIP Meeting)


















- ACIP changed the Hepatitis B [recommendation](#) for infants, including newborns, from universal to SCDM. ACIP also recommended evaluating the need for subsequent Hepatitis B doses in children based on antibody testing results.

### January 5, 2026

- CDC [announced](#) a new 2026 childhood immunization schedule that included six changes reflecting vaccine recommendations developed by federal health officials and two prior
-

ACIP-recommended changes (see COVID-19 changes under “May 27, 2025” and Hepatitis B changes under “December 4-5, 2025 (ACIP Meeting)” and **Figure 1**).

**Figure 1. Comparison of 2025 and 2026 Childhood Immunization Schedules**

DISEASE / VACCINES	PREV. CDC/ACIP RECOMMENDATION	2026 CDC RECOMMENDATION
 COVID-19*	All children	→ Shared Clinical Decision Making (SCDM)
 Dengue	Certain High-Risk Groups or Populations	Unchanged
 Diphtheria, tetanus, acellular pertussis (DTaP; Tdap)	All children	Unchanged
 Haemophilus influenzae type b (Hib)	All children	Unchanged
 Hepatitis A (HepA)	All children; Certain High-Risk Groups or Populations	→ Certain High-Risk Groups or Populations; SCDM for others
 Hepatitis B (HepB)*	All children	→ Certain High-Risk Groups or Populations; SCDM for others
 Human papillomavirus (HPV)	All children <i>Recommended 2 or 3 doses</i>	→ All children <i>Recommended doses reduced to 1</i>
 Inactivated poliovirus (IPV)	All children	Unchanged
 Influenza	All children	→ SCDM
 Measles, mumps, rubella (MMR)	All children	Unchanged
 Meningococcal B (MenB)	Certain High-Risk Groups or Populations; SCDM for others	Unchanged
 Meningococcal ACWY (MenACWY)	All children; Certain High-Risk Groups or Populations	→ Certain High-Risk Groups or Populations; SCDM for others
 Mpox	Certain High-Risk Groups or Populations	→ Unchanged / Not addressed
 Pneumococcal (PCV)	All children	Unchanged
 Respiratory syncytial virus (RSV-mAb)**	All children; Certain High-Risk Groups or Populations	→ Certain High-Risk Groups or Populations
 Rotavirus (RV)	All children	→ SCDM
 Varicella (VAR)	All children	Unchanged

**Source:** Figure developed by CRS. The “Prev. CDC/ACIP Recommendation” column is from [CDC, Recommended Child and Adolescent Immunization Schedule for Ages 18 Years and Younger, 2025](#). The “2026 CDC Recommendation” column is from [U.S. Department of Health and Human Services, Childhood Immunization Schedule by Recommended Group, 2026](#).

**Notes:** \*Changed by ACIP in 2025 and reaffirmed in the January 2026 schedule.

\*\*CDC previously categorized the recommendation to receive one-dose of RSV immunization as a recommendation for “All Children” and specified that this recommendation is for infants (<7 months) unprotected by maternal vaccination. The

CDC also recommended a second dose for “certain high-risk groups or populations.” The 2026 change maintains both recommendations but recategorizes the first recommendation of “All Children” as a recommendation for “Certain High-Risk Groups or Populations.”

## Current Status of Vaccine Recommendations

In *American Academy of Pediatrics v. Kennedy*, the U.S. District Court for the District of Massachusetts issued a stay on March 16, 2026, postponing the effective date of the revised 2026 childhood immunization schedule, the appointments of 13 ACIP members appointed by the HHS Secretary in June 2025, and all committee votes after June 11, 2025.

The stay stops the CDC from implementing changed vaccine recommendations after June 11, 2025, mostly reverting the childhood and adult immunization schedules to the 2025 versions (except for the April 2025 CDC/ACIP recommendations that remain in effect). The now-stayed ACIP members’ votes included a June 2025 vote to recommend a new RSV immunization, clesrovimab, for infants (as discussed above), which was not on the 2025 CDC immunization schedule. It is unclear whether a CDC/ACIP recommendation for clesrovimab remains, which could affect health care coverage of that immunization under federal law. The CDC/ACIP recommendation for the other RSV immunization for infants, nirsevimab, remains in effect.

Although the stay affected several 2025 and 2026 CDC vaccine recommendations, HHS may continue to change or issue new vaccine recommendations without violating the court’s order. On April 6, 2026, CDC published a *Federal Register* notice to renew a revised version of ACIP’s charter, which outlines ACIP’s objectives, scope of activities, and duties. The revised charter expands the potential scope of expertise for committee membership, modifies the committee’s objectives to focus more on vaccine safety considerations, and may signal that HHS/CDC intends to appoint new ACIP members. A newly formed committee could then vote on additional vaccine recommendations.

## Author Information

Kavya Sekar  
Specialist in Health Policy

Alexandria K. Mickler  
Analyst in Health Policy

---

## Disclaimer

This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan shared staff to congressional committees and Members of Congress. It operates solely at the behest of and under the direction of Congress. Information in a CRS Report should not be relied upon for purposes other than public understanding of information that has been provided by CRS to Members of Congress in connection with CRS’s institutional role. CRS Reports, as a work of the United States Government, are not subject to copyright protection in the United States. Any CRS Report may be reproduced and distributed in its entirety without permission from CRS. However, as a CRS Report may include copyrighted images or material from a third party, you may need to obtain the permission of the copyright holder if you wish to copy or otherwise use copyrighted material.